NCT04650490

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

A Randomized, Phase II Trial of SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is a randomized, 2-arm, phase II study to determine the effect, if any, of the timing of stereotactic radiosurgery (SRS) relative to immune checkpoint inhibitor (IO) therapy in patients with non-small cell lung cancer (NSCLC) that has spread (metastasized) to the brain.

Conditions

• Brain Metastases
• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	Stereotactic Radiosurgery	Timing of stereotactic radiosurgery relative to immunotherapy
DRUG	Immunotherapy	Physician's choice of immunotherapy per standard of care

Timeline

• Start date: 2023-03-01
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2020-12-02
• Last updated: 2023-03-02

Locations

1 site across 1 country: United States